MAT Troubleshooting

As the biopharmaceutical industry moves toward the mandatory suppression of animal-based pyrogen tests (Ph. Eur. 2.6.8) by January 2026, CellMade Laboratories provides an authoritative framework to bridge the gap between traditional assays and modern, human-relevant safety standards. Our services are specifically engineered to resolve the technical complexities—such as matrix interference, signal masking, and cytotoxicity—that frequently complicate Monocyte Activation Test (MAT) implementation for biologics.

Core Service Offerings:

• BDG Management & Validation (3-Phase Roadmap): A comprehensive strategy to identify and mitigate (1-3)-ß-D-glucan interference, utilizing targeted feasibility studies and method development to ensure accurate recovery in complex matrices.
• Targeted NEP Profiling: Precise root-cause analysis using a panel of human TLR-reporter cell lines. This allows for the characterization of specific non-endotoxin pyrogen (NEP) classes, providing investigative depth for Out-of-Specification (OOS) results.
• PBMC & Cytotoxicity Assessment: Mechanistic evaluation of cell viability and population-wide donor variability. We define the Maximum Non-Toxic Concentration and optimize cytokine monitoring (IL-6, IL-1ß, TNF-α) to guarantee assay robustness.
• Regulatory-Compliant Validation (Ph. Eur. & FDA/USP): We guide products from initial risk assessment to formal Product-Specific Verification (Ph. Eur. 2.6.30) or full validation (USP), ensuring seamless global market access and GMP-compliant routine testing.

The CellMade Advantage: By integrating iterative scientific development with rigid quality control standards, we provide a "Reproducibility Premium" for complex parenteral therapies. Our consultative approach ensures that your safety strategy is not only scientifically justified but fully aligned with the evolving 3Rs principles and global pharmacopoeial requirements.

Book an appointment for a technical consultation